From the theoretical point of view, antiproteolytic therapy would seem to be the rationale for acute pancreatitis management. Unfortunately, clinical human trials studying the role of antiproteases in the treatment of acute pancreatitis differ in several respects in terms of their basic design. As a consequence, any form of homogeneous analysis of the reported data as a whole is impossible. Considering the data emerging from a meta-analysis of five trials a rational use of antiproteases may result in a reduction of complications requiring surgery and of patient management costs only in selected cases, meaning by that severe and necrotic forms. As regards presumptive applications, over 400 patients were prospectively tested versus placebo in a double-blind trial with the aim of preventing acute pancreatitis after ERCP. The complication incidence was significantly lower among the pretreated patients; anyway, also in this field of protease inhibitor clinical application it is necessary to identify the patients with the greatest risk to develop post-ERCP acute pancreatitis. In conclusion, antiproteases can still play a role when given prophylactically or when used in the very early phases of the disease; moreover a ‘multiple drugs approach’ (including, for example, suitable antibiotics) seems to represent nowadays the most modern and rational treatment of acute pancreatitis.

Journal Section:
Acute Pancreatitis<br>Assessment and Treatment of Severe Acute Pancreatitis
Keywords:
Multiple drugs approach, Post-ERCP acute pancreatitis, Protease inhibitor, clinical applications, Pancreatitis, assessment and treatment
1.
Steinberg WM, Schlessmann SE: Treatment of acute pancreatitis: Comparison of animal and human studies. Gastroenterology 1987;93:1420&ndash;1427.
[PubMed]
2.
Trapnell JE, Rigby CC, Talbot CH, Duncan EHL: A controlled trial of trasylol in the treatment of acute pancreatitis. Br J Surg 1974;61:177&ndash;182.
[PubMed]
3.
Cox AG: Death from acute pancreatitis: MCR multicentre trial of glucagon and atropinin. Lancet 1977;24:632&ndash;635.
4.
Imrie CW, Benjamin IS, Ferguson JC, MaKay AJ, Mackenzie IM, O&rsquo;Neill J, Blumgart LH: A single-centre double-blind trial of trasylol therapy in primary acute pancreatitis. Br J Surg 1978;65:337&ndash;341.
[PubMed]
5.
Tanaka N, Tsuchiya R, Ishii K: Comparative clinical study of FOY and trasylol in acute pancreatitis. Adv Exp Med Biol 1979;1208:367&ndash;377.
6.
Yang CY, Chang-Chien CS, Liaw YF: Controlled trial of protease inhibitor gabexate mesilate (Foy) in the treatment of acute pancreatitis. Pancreas 1987;2:698&ndash;700.
[PubMed]
7.
Goebell H, for the German Pancreatitis Study Group: Multicenter double-blind study of gabexate mesilate (Foy), given intravenously in low dose in acute pancreatitis. Digestion 1988;40:83.
8.
Scuro LA, Cavallini G, Bovo P, Riela A, Bassi C, et al: Gabexate mesilate (Foy) treatment of acute pancreatitis. Clin Trial J 1990;27:39&ndash;49.
9.
Harada H, Miiyake H, Ochi K, Tanaka J, Kimura I: Clinical trial with a protease inhibitor gabexate mesilate in acute pancreatitis. Int J Pancreatol 1991;9:75&ndash;79.
[PubMed]
10.
Valderrama R, Perz Mateo M, Navarro S, Vasquez N, Sajose L, Adrian MV, Estruch J: Multicenter double-blind trial of gabexate mesilate (Foy) in acute pancreatitis. Digestion 1992;51:65&ndash;70.
[PubMed]
11.
Buchler M, Malfertheiner P, Uhl W, Scholmerich J, Stockman F, et al: Gabexate mesilate in human acute pancreatitis. Gastroenterology 1993;104:1165&ndash;1170.
[PubMed]
12.
Pederzoli P, Cavallini G, Falconi M, Bassi C, for the Italian GA.ME.PA. Study Group: Gabexate mesilate versus aprotinin in human acute pancreatitis: A prospective, randomised, double-blind multicenter study. Int J Pancreatol 1993;14:117&ndash;124.
[PubMed]
13.
Messori A, Rampazzo R, Scroccaro G, Olivato R, Bassi C, Falconi M, Pederzoli P, Martini N: Effectiveness of gabexate mesilate in acute pancreatitis: A meta-analysis. Dig Dis Sci 1995;40:734&ndash;738.
[PubMed]
14.
Warshaw A: Damage prevention versus damage control in acute pancreatitis. Gastroenterology 1993;104:1216&ndash;1218.
[PubMed]
15.
Yoschida T: Gabexate mesilate in human acute pancreatitis. Gastroenterology 1993;105:1922&ndash;1923.
16.
Cavallini G, Tittobello A, Frulloni L, et al: Gabexate for the prevention of pancreatic damage related to endoscopic retrograde cholangiopancreatography. N Engl J Med 1996;335:919&ndash;923.
[PubMed]
https://doi.org/10.1056/NEJM199609263351302
17.
Takeda K, Matsumo S, Sunamura M, Kakugama Y: Continuous regional arterial infusion of protease inhibitor and antibiotics in acute necrotizing pancreatitis. Am J Surg 1996;171:394&ndash;398.
[PubMed]
18.
Uomo G, Visconti M, Manes GP, Calise F, Laccetti M, Rabiatti PG: Nonsurgical treatment of acute necrotizing pancreatitis. Pancreas 1996;12:142&ndash;148.
[PubMed]
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
1999
You do not currently have access to this content.